Asthma

Antisense Product To Be Developed

Published in Gene Therapy Weekly, March 23rd, 2000

Taisho Pharmaceutical Co., Ltd., Tokyo, Japan, and EpiGenesis Pharmaceuticals, Inc., Cranbury, New Jersey, jointly announced that they have entered into a binding Letter of Intent encompassing an exclusive development and licensing agreement for the Asian market for EPI-2010.

EPI-2010 is a respirable antisense oligonucleotide (RASON) for asthma.

Antisense oligonucleotides are a new class of pharmaceuticals that act by attenuating the actual production of disease-related proteins. EpiGenesis has pioneered a new form of antisense oligonucleotides known as RASONs, designed for direct application to the lung via aerosol inhalation. In this manner, a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry